Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The cardiovascular system is the second most common target of SARS-CoV-2, which leads to severe complications, including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism, as well as other major thrombotic events because of direct endothelial injury and an excessive systemic inflammatory response. This review focuses on the similarities and the differences of inflammatory pathways involved in COVID-19 and atherosclerosis. Anti-inflammatory agents and immunomodulators have recently been assessed, which may constitute rational treatments for the reduction of cardiovascular events in both COVID-19 and atherosclerotic heart disease.

Original publication

DOI

10.3390/ijms22126607

Type

Journal article

Journal

Int J Mol Sci

Publication Date

21/06/2021

Volume

22

Keywords

COVID-19, SARS-CoV-2, anti-inflammatory treatment, atherosclerosis, inflammation, Adrenal Cortex Hormones, Anti-Inflammatory Agents, Atherosclerosis, COVID-19, Chemokines, Cytokine Release Syndrome, Cytokines, Humans, Prognosis, SARS-CoV-2